Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Proactive Investors

06:37 EST 17th January 2019 | BioPortfolio

Here are the most relevant search results for "Proactive Investors" found in our extensive news archives from over 250 global news sources.

More Information about Proactive Investors on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Proactive Investors for you to read. Along with our medical data and news we also list Proactive Investors Clinical Trials, which are updated daily. BioPortfolio also has a large database of Proactive Investors Companies for you to search.

Showing News Articles 1–25 of 2,100+ from Proactive Investors

Wednesday 16th January 2019

VBI Vaccines shares pop after Oppenheimer analyst kicks off coverage with Outperform rating

Oppenheimer's Leland Gershell thinks positive news flow from any of VBIV's three vaccine programs could trigger share price appreciation

Collagen Solutions inks significant manufacturing deal for wound-healing product

Jamal Rushdy, chief executive of Collagen Solutions PLC (LON:COS), discusses with Proactive Investors a manufacturing agreement that's been reached for the Excellagen product with Olaregen Therapeutix - a New York-based firm focused on products in the wound care market. Collagen will manufacture Excellagen for Olaregen following a deal signed in September 2018 between the latter and US biotech...

Allergy Therapeutics higher as revenues rise 10.6%, cash reserves grow

The drug developer's trading statement revealed the latest numbers were in line with market forecasts

QBioMed appoints Yale psychologist to advisory committee

Dr Pamela Ventola works at Yale University’s Child Study Center where she focuses on behavioral treatments for autism

Itaconix PLC CEO on exclusive global agreement with Nouryon

John R. Shaw, chief executive of Itaconix Plc (LON:ITX) caught up with Proactive London's Andrew Scott following the announcement they'd signed an exclusive global agreement with Nouryon, formerly AkzoNobel Specialty Chemicals, to supply it with its bio-based polymers with chelating properties for the detergents market. The deal follows Itaconix's announcement in May 2018 that Nouryon had noti...

Medical expert discusses his experience working with Shield Therapeutics' Feraccru drug

Dr Fraser Cummings,  a consultant gastroenterologist at Southampton General Hospital, spoke to Proactive's Andrew Scott while in London. ''One of the big advantages of Feraccru is that it's extremely well tolerated in the actually quite difficult group of patients who've already failed oral therapies and are quite anxious about taking another iron tablet ... but our data shows that patien...

Allergy Therapeutics revenues rise 10.6% as cash reserves grow

The drug developer's trading statement revealed the latest numbers were in line with market forecasts

Tuesday 15th January 2019

Shore Capital sees number of “potentially exciting” product applications for Eden Research pending authorisations

“Whilst authorisations need to come through, the length and breadth of activity is genuinely encouraging to our minds and we expect momentum to further build in FY2019"

Microbot extends rally after citing progress with self-cleaning shunt used in hydrocephalus treatment

Separately, the company announced the $3 million registered direct offering of shares to an institutional investor

Haydale Graphene jumps on deal to supply 76kg of its propriety piezoresistive ink to HP1 Technologies

The AIM-listed advanced materials group said the value of the supply agreement is not disclosed due to its commercially sensitive nature

Silence Therapeutics higher as lead medicine candidate granted orphan drug status

Orphan drug status gives drugmakers certain benefits to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive

Eden Research positioned for growth after 'pleasing' performance in 2018

Sean Smith, CEO of Eden Research PLC (LON:EDEN), tells Proactive London they're expecting to report full-year 2018 revenue of 48% and a modest operating profit after a year of “pleasing growth”. Smith says the majority of revenue growth came from product sales which doubled in 2018 to around £1.6mln, up from £0.8mln in 2017, with the balance the revenue being made up of upfront, mileston...

NetScientific says continuing to assess all remaining strategic options after closing formal sale process

The transatlantic healthcare IP commercialisation group announced on 26 November 2018 that it had decided to conduct a review of the various strategic options open to it, one of which was a sale

OZOP Surgical makes headway on bringing its spine implant tech to market

OZOP Surgical Corp (OTCQB:OZSC) COO Thomas McLeer tells Proactive Investors the medical device company is making headway with its surgical implant devices. McLeer says over the next year the Florida based company is developing the first percutaneous spinal fusion implant system to allow the delivering of a spine implant through a very small tube.

Itaconix surges as it inks deal with Nouryon to supply bio-based polymers for use in the detergents market

John R. Shaw, Itaconix’s CEO commented: "We expect the supply arrangement will support a significant part of our forecast detergent revenues for 2019 and beyond"

Eden Research expects to report 48% jump in revenue, modest operating profit after year of “pleasing growth”

The AIM-listed company said its 2018 revenue is expected to be in the region of £2.8mln, up from £1.9m in 2017, with a loss before tax of approximately £1.0mln, versus a £0.8mln loss in 2017

Collagen Solutions rises as it signs manufacturing agreement for Excellagen wound-healing product

Collagen will manufacture Excellagen for New York-based Olaragen following a deal signed in 2018 between the latter and Gene Biotherapeutics, for whom Collagen originally made the product

TransEnterix's digital laparoscopy device gets green light from FDA

The company's Senhance Ultrasonic system is approved for use in the US for laparoscopic colorectal, gynecological and gallbladder removal surgery

Genedrive receives second order from US Department of Defense

The company is targeting around 30 country registrations for the Genedrive HCV ID Kit by the end of June.

Sativa Investments appoints head of new retail arm

Earlier this month NEX-listed Sativa, which was set up as a vehicle to invest in medicinal cannabis, announced plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada

Clinigen to report sharp jump in revenue and profit after busy six months

The AIM billionaire has bought two new drugs in the past six months, while it has also snapped up two companies

MaxCyte says earnings likely to beat expectations after bumper end to the year

Revenues increased 19% year-on-year to US$16.7mln in the 12 months to December 31, with top-line growth of 25% in the second six months

Haydale Graphene signs deal to supply 76kg of its propriety piezoresistive ink to HP1 Technologies

The AIM-listed advanced materials group said the value of the supply agreement is not disclosed due to its commercially sensitive nature

Silence Therapeutics’ lead medicine candidate granted orphan drug status

Orphan drug status gives drugmakers certain benefits in order to encourage them to develop treatments for rare diseases which might otherwise lack sufficient profit motive

Monday 14th January 2019

Itaconix seeing commercial momentum building and expansion of revenue potential

John Shaw, chief executive of Itaconix Plc (LON:ITX), caught up with Proactive's Andrew Scott while in London. Shaw took took over as chief executive as part of a reshuffle at the company in late 2018. Shaw says the big focus for 2019 is on converting their pipeline of customer projects into revenue growth.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks